Strategic Intent: Understanding Crossover Strategies in Biotech With Sofinnova Partners’ David Evans
In this episode of Strategic Intent, Partner at Sofinnova Partners, David Evans discusses his transition from Roche Venture Fund, different...
Radio and PodcastLive Radio & Podcasts
Business
Pharma Intelligence Podcasts
Pharma Intelligence from Informa places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfe...
Episodes
20 of 634 episodes
Scrip Awards Podcast – Parabilis CEO Mathai Mammen Interview
Ahead of the awards presentation on Dec 2, the Scrip Awards podcast speaks to Mathai Mammen, CEO of Parabilis, one of the shortlisted compan...
Strategic Intent: Can Blood Tests Break the Alzheimer’s Diagnosis Bottleneck?
Disease-modifying Alzheimer’s treatments have arrived, but diagnosing the right patients at scale is still a major bottleneck. In this episo...
Off-Patent, On Record: Unlocking The Value Of Biosimilars Beyond Savings With IGBA’s Ana Gaunt
In the latest episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė talks to the International Generic a...
Drug Fix: What Drove US FDA Generics Chief To Step Down And New Rare Disease Framework
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the reasons Iilun Murphy, di...
Scrip Chinese-Language Podcast - Oct. 14, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本周内容包括：中国带来的竞争威胁；第三季度并购活动降温；新型肺炎球菌疫苗竞争者；西班牙生物技术公司的战略；以及盐野义制药20亿美...
Digital Health Roundup: BD’s $19Bn Tariff Deal, Longevity, GLP-1 Tools Chasing Proof
In this month's podcast, Shubham Singh discusses BD’s $19bn US investment deal for tariff relief; Brian Bossetta, NET Recovery’s stimulant-u...
Scrip's Five Must-Know Things - Oct. 13, 2026
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, i...
Strategic Intent: Celebrity Marketing In The Age Of Promo Crackdown
Can a celebrity campaign still work for a drug company when the FDA is watching every word? In this episode of Strategic Intent, Frank Watan...
Drug Fix: US FDA’s Peptide Drama, More Transparency, Ibogaine Clinical Trial Plans
Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Senior Editor Sue Sutter and Senior Reporter Maaisha Osman d...
Off-Patent, On Record: Navigating The Financial Strategy Behind Litigation With Sandoz’s Julia Pike
In the third episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė is joined by Sandoz’s head of IP Juli...
Strategic Intent: Using Agentic AI To Create ‘The Self-Driving Clinical Trial, Kind Of Like The Car’
In this Strategic Intent episode, In Vivo speaks with Ken Getz, executive director of the Tufts CSDD and research professor at the Tufts Uni...
Counting Self-Care’s Triple Win, With GSCF’s Greg Perry And Ben Carrick
The Global Self-Care Federation has updated its analysis of the health, social and economic value of self-care, using data from 155 countrie...
Drug Fix: CMS Finalizes GLOBE Model And US FDA Adcomm, Personnel Changes
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Senior Writer Cathy Kelly discuss the limited impact the US Center...
Proof of Concept - Can AI Outrun the Next Outbreak?
What if you could design a diagnostic and a therapeutic directly from a pathogen's genetic code, faster than the disease can spread? Jared B...
【3分で解説 #世界のファーマ】第31回 中国、バイオ医薬品の成長に本腰 初の5カ年計画 (Japanese-language podcast) Sept. 30, 2026
世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。今回取り上げた記事はこちら Six Chinese Drugs On Co...
Strategic Intent: Boehringer Ingelheim's Brian Hilberdink on Launching Into the GLP-1 Era
Brian Hilberdink, President of US Human Pharma at Boehringer Ingelheim, joined Strategic Intent to talk about leading one of the company's m...
Drug Fix: Lessons From US FDA Commissioner Nominee Heidi Overton’s Confirmation Hearing
Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs disse...
Assessing the current dealmaking environment for psychedelic medicine.
Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's...
Strategic Intent: Rubedo’s Seno-Adaptive Bet On Longevity Medicine
In this episode of Strategic Intent, In Vivo senior reporter David Wild speaks with Frederick Beddingfield, CEO of Rubedo Life Sciences, abo...